It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Thymic atrophy in sepsis is a critical disadvantage because it induces immunosuppression and increases the mortality rate as the disease progresses. However, the exact mechanism of thymic atrophy has not been fully elucidated. In this study, we discovered a novel role for VSIG4-positive peritoneal macrophages (V4(+) cells) as the principal cells that induce thymic atrophy and thymocyte apoptosis. In CLP-induced mice, V4(+) cells were activated after ingestion of invading microbes, and the majority of these cells migrated into the thymus. Furthermore, these cells underwent a phenotypic shift from V4(+) to V4(−) and from MHC II(low) to MHC II(+). In coculture with thymocytes, V4(+) cells mainly induced apoptosis in DP thymocytes via the secretion of TNF-α. However, there was little effect on CD4 or CD8 SP and DN thymocytes. V4(−) cells showed low levels of activity compared to V4(+) cells. Thymic atrophy in CLP-induced V4(KO) mice was much less severe than that in CLP-induced wild-type mice. In addition, V4(KO) peritoneal macrophages also showed similar activity to V4(−) cells. Taken together, the current study demonstrates that V4(+) cells play important roles in inducing immunosuppression via thymic atrophy in the context of severe infection. These data also suggest that controlling the function of V4(+) cells may play a crucial role in the development of new therapies to prevent thymocyte apoptosis in sepsis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Innovative Therapeutics Research Institute, College of Medicine, Inje University, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112)
2 Innovative Therapeutics Research Institute, College of Medicine, Inje University, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112); Inje University College of Medicine, Department of Microbiology and Immunology, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112)
3 College of Medical & Institute of Environmental and Occupational Medicine, Inje University, Department of Occupational and Environmental Medicine, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112)
4 Innovative Therapeutics Research Institute, College of Medicine, Inje University, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112); College of Medicine, Inje University, Department of Convergence Biomedical Science, Busan, Republic of Korea (GRID:grid.411612.1) (ISNI:0000 0004 0470 5112)